Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

70.91
+0.51000.72%
Post-market: 71.510.6000+0.85%18:39 EDT
Volume:372.14K
Turnover:26.28M
Market Cap:3.94B
PE:6.39
High:71.08
Open:70.33
Low:70.13
Close:70.40
52wk High:74.59
52wk Low:59.47
Shares:55.60M
Float Shares:55.60M
Volume Ratio:0.78
T/O Rate:0.67%
Dividend:0.81
Dividend Rate:1.14%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.41
PE(LYR):23.18

Loading ...

UnitedHealth - Appoints Jodee Kozlak as Chief Administrative Officer Effective Sept. 28, 2026

THOMSON REUTERS
·
Sep 24

Merck's Drug for Diabetes-Related Eye Disease Meets Trial Goal

Reuters
·
Sep 24

Health Canada Approves AbbVie’s Epkinly Combo for Relapsed or Refractory Follicular Lymphoma in Adults

Reuters
·
Sep 24

Epkinly® Receives Health Canada Approval for Adults with Follicular Lymphoma

THOMSON REUTERS
·
Sep 24

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Dow Jones
·
Sep 24

Merck Says Remigromig Meets Primary Endpoint in Pivotal Brunello Trial for Diabetic Macular Edema

Reuters
·
Sep 24

Eli Lilly - Onswik Kwikpen to be Available in U.S. in 500 Units/Ml and 1,000 Units/Ml Concentrations

THOMSON REUTERS
·
Sep 24

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

THOMSON REUTERS
·
Sep 24

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 24

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Sep 24

Johnson & Johnson (JNJ) Receives a Buy from RBC Capital

TIPRANKS
·
Sep 24

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

TIPRANKS
·
Sep 24

Medtronic PLC Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Exchange-Traded Funds, US Equities Decline After Midday

MT Newswires Live
·
Sep 24

Johnson & Johnson Says New Analysis of Ongoing Phase 3 Trial Data Supports Potential of Multiple Myeloma Combination Therapy

MT Newswires Live
·
Sep 23